- Conditions
- Mild Cognitive Impairment, Aging
- Interventions
- 18F-MK-6240
- Drug
- Lead sponsor
- Yaakov Stern
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
- Interventions
- [ 18F]3F4AP, [18F]MK6240, [11C]PIB
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease, Healthy Volunteers
- Interventions
- [18F] MNI-946, [18F]Florbetapir
- Drug
- Lead sponsor
- Invicro
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, Lumbar Puncture (optional)
- Drug · Procedure
- Lead sponsor
- Patrick Lao
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- MK 6240
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease
- Interventions
- 18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
- Drug
- Lead sponsor
- Tharick Pascoal
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 822 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
- Conditions
- Alzheimer Disease
- Interventions
- 11C-ER176, 18F-MK6240, 18F-Florbetaben, Lumbar Puncture
- Drug · Procedure
- Lead sponsor
- Patrick Lao
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy, Alzheimer Disease
- Interventions
- [F18]RO-948, [F18]MK-6240, [F18]AV1451
- Diagnostic Test
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 100 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Interventions
- Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
- Diagnostic Test
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Down Syndrome
- Interventions
- [18F]MK-6240
- Biological
- Lead sponsor
- LuMind IDSC Foundation
- Other
- Eligibility
- 35 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, 11C-PIB
- Drug
- Lead sponsor
- José A. Luchsinger
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
- Device · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Orangeburg, New York
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetes
- Interventions
- 18F-MK6240 injection
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 55 Years to 69 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- [18F]RO-948, 18F-MK6240, 18F-GTP1
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Interventions
- Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 45 more
- Conditions
- Alzheimer Disease (AD)
- Interventions
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, 18F-Florbetaben
- Drug
- Lead sponsor
- Adam Brickman
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
- Device · Drug · Other + 2 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- All Subjects
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin